Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and activity of preoperative pembrolizumab combined with
chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients
enrolled in Phase Ib PALACE-1(NCT03792347).The results showed that preoperative pembrolizumab
with concurrent chemoradiotherapy was safe, did not delay surgery and induced a pCR in 55.6%
of resected tumors. In this multicentre prospective study(PALACE-2),the investigators will
evaluate the efficacy of preoperative pembrolizumab with concurrent chemoradiotherapy in
patients with locally advanced esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Fujian Medical University Union Hospital The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Nanchang University Zhejiang University